The first bank of China fund to release its second Quarterly Report
As of 3 p.m. today, BOC fund disclosed the second quarterly report of nine products, including one flexible configuration product, two commodity based products and six debt based products. Among them, the net asset value of Bank of China Healthcare fund managed by Liu Xiao reached 1.264 billion yuan (A / C combined calculation) at the end of the second quarter, with a growth rate of 17.88% in the quarter. Compared with the previous quarter, Beida pharmaceutical, Aier ophthalmology and Lizhu group were newly added to the top ten heavy position stocks of the fund; And Yunnan Baiyao increased its position by 208500 shares, which is the largest position of the fund; Changchun hi tech, Zhifei biology, humanwell medicine, etc. withdrew from the top ten heavy position stocks. Fund managers said that their positions focused on innovative drugs, cro / cdmo and other industry leaders, and focused on the rise of domestic life technology industry supply chain.
This text is a result of machine translation.
Related companies：
Briefing Updated 1 hour ago
Taier shares: the contract dispute case against Cao Linbin was accepted by the court
In-depth
Healthcare
Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying
The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?
Feb 21, 2022 02:30 PM
Briefing Apr 27, 2022 05:16 PM
Beautiful Ecology: the net profit in the first quarter increased by 24.92% to 1.9755 million yuan
Apr 18, 2022 06:30 PM
Apr 22, 2021 03:11 PM
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Briefing Apr 25, 2022 06:25 PM
· Healthcare
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
Healthcare
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Digital Zhengtong: new orders signed in the first two months increased by more than 60% year-on-year
Briefing Mar 15, 2022 12:19 PM
Half day main capital net inflow of power equipment, non bank finance, selling banks, etc
In-depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
See more
Read next
In-depth
In-depth
Financials, Healthcare
Exclusive Interview with Zhou Mi, Managing Partner of Puhua Capital
May 12, 2022 05:41 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.